CoChat
Sign Up
Cited by 173

The DOI matches its Crossref record.

Efficacy of L-Ornithine L-Aspartate in Acute Liver Failure: A Double-Blind, Randomized, Placebo-Controlled Study

Acharya, Subrat Kumar, Bhatia, Vikram, Sreenivas, Vishnubhatla, Khanal, Shankar, Panda, Subrat Kumar·2009·Gastroenterology
DOI 10.1053/j.gastro.2009.02.050
Open this paper in CoChat — free account

Abstract

Background & aims In acute liver failure (ALF), high blood ammonia levels have been documented that correlate with mortality and complications. L-ornithine L-aspartate (LOLA) reduces ammonia levels by increasing hepatic ammonia disposal and its peripheral metabolism. Present study evaluated efficacy and ammonia lowering effect of LOLA in ALF. Methods This study was placebo-controlled and blinded. We randomized 201 patients with ALF between January 2005 and October 2007 to either placebo or LOLA infusions (30 g daily) for 3 days. Arterial ammonia was measured at baseline and daily for 6 days. The primary end point was improvement in survival. The study followed CONSORT guidelines and was registered at the ClinicalTrials.gov (Identifier: NCT00470314). Results There was no reduction in mortality with LOLA treatment (mortality: 33.3% in placebo and 42.4% in LOLA; relative risk of death 1.27; 95% CI: 0.88-1.85; P = .204). By multivariate analysis, ammonia levels were an independent predictor of survival. There was significant decrease in ammonia levels in both groups with time (P Conclusions LOLA infusion did not lower the ammonia or improved survival in ALF.

Overview

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2009.02.050

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 30

  1. Strauss, 2001, Cerebral metabolism of ammonia and amino acids in patients with fulminant hepatic failure, Gastroenterology, 121, 1109, 10.1053/gast.2001.29310 · DOI
  2. Chatauret, 2004, Effects of liver failure on inter-organ trafficking of ammonia: implications for the treatment of hepatic encephalopathy, J Gastroenterol Hepatol, 19, S219, 10.1111/j.1440-1746.2004.03648.x · DOI
  3. Jones, 2002, Ammonia, the GABA neurotransmitter system, and hepatic encephalopathy, Metab Brain Dis, 17, 275, 10.1023/A:1021949616422 · DOI
  4. Clemmesen, 1999, Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration, Hepatology, 29, 648, 10.1002/hep.510290309 · DOI
  5. Kundra, 2005, Evaluation of plasma ammonia levels in patients with acute liver failure and chronic liver disease and its correlation with the severity of hepatic encephalopathy and clinical features of raised intracranial tension, Clin Biochem, 38, 696, 10.1016/j.clinbiochem.2005.04.013 · DOI
  6. Bhatia, 2006, Predictive value of arterial ammonia for complications and outcome in acute liver failure, Gut, 55, 98, 10.1136/gut.2004.061754 · DOI
  7. Bernal, 2007, Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure, Hepatology, 46, 1844, 10.1002/hep.21838 · DOI
  8. Zieve, 1986, Ammonia toxicity: comparative protective effect of various arginine and ornithine derivatives, aspartate, benzoate and carbamyl glutamate, Metab Brain Dis, 1, 25, 10.1007/BF00998474 · DOI
  9. Albrecht, 1994, Increase of the brain uptake index for L-ornithine in rats with hepatic encephalopathy, Neuroreport, 5, 671, 10.1097/00001756-199402000-00002 · DOI
  10. Rose, 1998, L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action, Metab Brain Dis, 13, 147, 10.1023/A:1020613314572 · DOI
  11. Kircheis, 2002, Clinical efficacy of L-ornithine-L-aspartate in the management of hepatic encephalopathy, Metab Brain Dis, 17, 453, 10.1023/A:1021934607762 · DOI
  12. Rose, 1999, L-ornithine-L-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure, Hepatology, 30, 636, 10.1002/hep.510300311 · DOI
  13. Tandon, 1999, Recommendations of the International Association for the Study of the Liver Subcommittee on nomenclature of acute and sub acute liver failure, J Gastroenterol Hepatol, 14, 403, 10.1046/j.1440-1746.1999.01905.x · DOI
  14. Altman, 2001, The revised CONSORT statement for reporting randomized trials: explanation and elaboration, Ann Intern Med, 134, 663, 10.7326/0003-4819-134-8-200104170-00012 · DOI · Paper page
  15. Acharya, 1996, Fulminant hepatitis in a tropical population: clinical course, cause and early predictors of outcome, Hepatology, 23, 1448, 10.1002/hep.510230622 · DOI
  16. Jameel, 1992, Enteric non-A, non-B hepatitis: epidemics, animal transmission, and hepatitis E virus detection by the polymerase chain reaction, J Med Virol, 37, 263, 10.1002/jmv.1890370405 · DOI
  17. Riegler, 1993, Fulminant hepatic failure, Med Clin North Am, 77, 1057, 10.1016/S0025-7125(16)30210-3 · DOI
  18. Staedt, 1993, Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis, J Hepatol, 19, 424, 10.1016/S0168-8278(05)80553-7 · DOI
  19. Kircheis, 1997, Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study, Hepatology, 25, 1351, 10.1002/hep.510250609 · DOI
  20. Stauch, 1998, Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study, J Hepatol, 28, 856, 10.1016/S0168-8278(98)80237-7 · DOI
  21. Poo, 2006, Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy, Ann Hepatol, 5, 281, 10.1016/S1665-2681(19)31989-1 · DOI
  22. Clemmesen, 2000, Splanchnic and leg exchange of amino acids and ammonia in acute liver failure, Gastroenterology, 118, 1131, 10.1016/S0016-5085(00)70366-0 · DOI
  23. Rosen, 1977, Plasma amino acid patterns in hepatic encephalopathy of differing etiology, Gastroenterology, 72, 483, 10.1016/S0016-5085(77)80261-8 · DOI
  24. Clemmesen, 2001, Effects of high-volume plasmapheresis on ammonia, urea, and amino acids in patients with acute liver failure, Am J Gastroenterol, 96, 1217, 10.1111/j.1572-0241.2001.03706.x · DOI
  25. Rees, 2000, Effect of L-ornithine-L-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial, Gut, 47, 571, 10.1136/gut.47.4.571 · DOI
  26. Alba, 2002, Lactulose therapy in acute liver failure, J Hepatol, 36, 33A, 10.1016/S0168-8278(02)80097-6 · DOI
  27. Polson, 2005, AASLD position paper: the management of acute liver failure, Hepatology, 41, 1179, 10.1002/hep.20703 · DOI
  28. Sushma, 1992, Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial, Hepatology, 16, 138, 10.1002/hep.1840160123 · DOI
  29. Efrati, 2000, Effect of sodium benzoate on blood ammonia response to oral glutamine challenge in cirrhotic patients: a note of caution, Am J Gastroenterol, 95, 3574, 10.1111/j.1572-0241.2000.03295.x · DOI
  30. Palekar, 1989, Failure of sodium benzoate to alleviate plasma and liver ammonia in rats, Biochem Med Metab Biol, 41, 64, 10.1016/0885-4505(89)90009-1 · DOI

Cited by

Sorted by citations

Metadata

Authors
Acharya, S. K., Bhatia, V., Sreenivas, V., Khanal, S., & Panda, S. K.
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2009-06
Volume
136
Issue
7
Pages
2159-2168
ISSN
0016-5085
DOI
10.1053/j.gastro.2009.02.050
Cited by
173
References
0
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review